Buying guide

Versius vs Maestro in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, Versius is further along: at the commercial stage versus Maestro at the pilot stage, as of 2026.

Maestro has the lower recorded price.
Versius has more verified real-world deployments (4 vs 1).
Versius is at the commercial stage; Maestro at the pilot stage.

Attribute	Versius View full model page →	No image on file Maestro View full model page →
Manufacturer	CMR Surgical	Moon Surgical
Form factor	surgical	surgical
Maturity	commercial	pilot
Autonomy	◐ not independently verified	◐ not independently verified
Availability	internal-onlyenterprise	internal-onlyenterprise
Price	$750,000-$1,000,000 (analyst estimate)	$300,000-$800,000 (analyst estimate)
Capability claims	Assists surgery (teleoperated-assisted, claimed)	Assists surgery (teleoperated-assisted, verified)
Brain	—	—
Verified deployments	4	1Moon Surgical
Privacy practices	—	—
Sources on file	24	9

Track this matchup

Get told the moment Versius or Maestro changes. Verified changes only, the second they are real. No press-release noise.

Versius

Maestro

Editorial summaries

Versius

CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data.

On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.

Maestro

Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.

On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.

Common questions

How do Versius and Maestro differ?

On DEPLOY's record, Versius is further along: at the commercial stage versus Maestro at the pilot stage, as of 2026. Maestro has the lower recorded price. Versius has more verified real-world deployments (4 vs 1). Versius is at the commercial stage; Maestro at the pilot stage.

What is the difference between Versius and Maestro?

Versius and Maestro are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.

Which is cheaper, Versius or Maestro?

Maestro has the lower recorded price on the DEPLOY registry than Versius. Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.

Is Versius or Maestro more autonomous?

On the DEPLOY registry, neither Versius nor Maestro has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.

Which has more verified deployments, Versius or Maestro?

Versius has more verified deployments (4) on the DEPLOY registry than Maestro (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Escuelas del Condado Clark inician nuevo ciclo con enfoque en matemáticas y lecturaMaestro · The Nevada Independent · 2026-08-12
Moon Surgical wins first FDA 510(k) clearance for surgical robotMaestro · Ben Smith, Deploy Editor · 2026-06-25
CMR Surgical secures 510k clearance of Versius Plus robotic surgical systemVersius · Ben Smith, Deploy Editor · 2026-06-09
FDA Clears New Robotic Platform for Gallbladder SurgeryVersius · Ben Smith, Deploy Editor · 2025-12-17

Related comparisons

Keep researching

Keep reading

All surgical robotsRegistry Every verified record in the category.VersiusModel The full model page.MaestroModel The full model page.CMR SurgicalRecord The maker's verified record.Moon SurgicalRecord The maker's verified record.Versius vs da Vinci (and Ion)Compare Another head-to-head.

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructions Download for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots